ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ADVM Adverum Biotechnologies Inc

10.43
0.43 (4.30%)
04 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Adverum Biotechnologies Inc NASDAQ:ADVM NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.43 4.30% 10.43 9.75 44.43 10.69 10.00 10.10 900,531 05:00:01

Adverum Biotechnologies to Present at the Jefferies Global Healthcare Conference

22/05/2017 1:30pm

GlobeNewswire Inc.


Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Adverum Biotechnologies Charts.

Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a leading gene therapy company advancing novel medicines to address unmet needs in serious rare and ocular diseases, announced today that Amber Salzman, Ph.D., president and chief executive officer, will present at the Jefferies Global Healthcare Conference.

  
Event:Jefferies Global Healthcare Conference
  
Date:June 7, 2017
  
Time:1:30 – 2:00 p.m. ET
  
Location:New York, NY
  

A live and replay video webcast of the presentation will be available from Adverum’s website at http://investors.adverum.com.

About Adverum Biotechnologies, Inc.Adverum is a gene therapy company advancing novel medicines that can offer life-changing benefits to patients living with serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat wet age-related macular degeneration (wAMD) and rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE).  Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, the Company generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum’s core capabilities include clinical development and in-house manufacturing expertise, specifically in process development and assay development. For more information please visit www.adverum.com.

Contacts for Adverum:

Leone Patterson
Chief Financial Officer
Adverum Biotechnologies, Inc.
650-665-7222
lpatterson@adverum.com

Tricia Truehart            
Vice President
The Trout Group LLC
646-378-2953
ttruehart@troutgroup.com

1 Year Adverum Biotechnologies Chart

1 Year Adverum Biotechnologies Chart

1 Month Adverum Biotechnologies Chart

1 Month Adverum Biotechnologies Chart

Your Recent History

Delayed Upgrade Clock